培菲康辅助序贯疗法根除幽门螺杆菌的临床观察

Bifid Lriple Viable facilitates the sequential therapy for Helicobacter pylori eradication

目的比较序贯疗法联合培菲康与序贯疗法治疗幽门螺杆菌(Hp)阳性十二指肠溃疡的疗效与安全性。方法选取84例经胃镜检测证实为Hp阳性十二指肠溃疡病例,随机分为治疗组与对照组,两组均前5d予雷贝拉唑、阿莫西林,后5d予雷贝拉唑、替硝唑、克拉霉素治疗。随后两组均进行雷贝拉唑巩固治疗4周,治疗组全程均辅加培菲康,疗程结束后均行复查。结果疗程结束时,治疗组溃疡愈合率95.12%,对照组93.02%(P>0.05);Hp根除率治疗组97.56%,明显高于对照组81.40%,且具有显著性差异(P<0.05);治疗组不良反应明显少于对照组(P<0.05)。结论两组溃疡愈合率相当,但培菲康提高了序贯疗法的Hp根除率,且不良反应少,耐受好,安全。

Objective Tocompare the efficiency and safety between sequential the rapy and sequential therapy combined with Bifid Lriple Viable in Helicobacter pylori（H.pylori）-positive duodenal ulcer patients.Methods Eighty-four patients with H.pylori-positive duodenal ulcer,confirmed by endoscopy,were randomly divided into treatment group and control group,and both groups accepted the same remedy：rabeprazole,amoxicillin for the first 5d,rabeprazole,tinidazole,clarithromycin for the folloeing 5 d.Both groups were followed for 4 weeks,and the treatment group additionally accepted Bifid Lriple Viable treatment during the full course.Review was performed at the end of treatment.Results The ulcer healing rate in treatment group was 95.12%,and the control group was 93.02% （P 0.05）;H.pylori eradication rate in treatment group was 97.56%,and in control group was 81.40% （P 0.05）;the side effects in treatment group was significantly lower than in control group （P 0.05）.Conclusions Sequential therapy combined with Bifid Lriple Viable facilitates the H.pylori eradication rate,with less adverse effects.